Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Enhanced PHA stimulation of cancer patients' lymphocytes by addition of BM 12531 (azimexon) in vitro

  • 8 Accesses

  • 3 Citations

Summary

Lymphocytes of seven patients with advanced cancer were investigated for changes of blastogenic response to PHA after the addition of the new immunomodulating compound 2-[2-cyanaziridinyl-(1)]-2-[2-carbamoyl-aziridinyl-(1)]-propane (BM 12 531; prop. INN azimexon) to in vitro cultures. Concentrations of 0.2, 1, 2.5, 5, and 10 μg/ml were added to cultures. Significant changes in 3H-thymidine uptake were observed with all concentrations of BM 12 531. The most pronounced increase was observed with the concentration of 0.2 μg/ml, i.e., five of seven patients had a significantly enhanced blastogenesis response to PHA. Higher doses were effective only in some of the lymphocyte cultures, and stimulation was always lower than with 0.2 μg. These observations suggest an interaction of BM 12 531 and lymphocyte activation at a molecular level.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Amery, W. K.: Overview of other controlled clinical data: an attempt at defining the future position of levamisole in cancer therapy. In: Immunotherapy of malignant disease, p. 112. Stuttgart, New York: Schattauer 1978

  2. 2.

    Bast, R. C., Zbar, B., Borsos, T., Rapp, H. J.: BCG and cancer. N. Engl. J. Med. 290, 1413 (1974)

  3. 3.

    Bicker, U.: BM 06 002: A new immune stimulating drug. In: Immune modulation and control of neoplasia by adjuvant therapy. Prog. Cancer Res. Ther. 7, 389 (1978a)

  4. 4.

    Bicker, U.: Immunomodulating effects of BM 12 531 in animals and tolerance in man. In: Proceedings of the Fourth Conference on Immunomodulation and Control of Neoplasia by Adjuvant Therapy (in press, 1978b)

  5. 5.

    Bicker, U., Fuhse, P.: Carcinostatic action of 2-zyanaziridines against a sarcoma in rats. Exp. Pathol. (Jena) 10, 279 (1975)

  6. 6.

    Bicker, U., Ziegler, A. E., Hebold, G.: 2-[2-cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, BM 12 531: a new substance with immune stimulating action. IRCS Med. Sci. 5, 299 (1977)

  7. 7.

    Bonfert, B., Bicker, U., Hebold, G., Maus, W.: Increased phagocytosis of latex particles as a sign of activation of macrophages by BM 12 531. IRCS Med. Sci. 5, 523 (1977)

  8. 8.

    Copeland, D., Stewart, T., Harris, J.: Effect of levamisole NSC-177023) on in vitro human lymphocyte transformation. Cancer Chemother. Rep. 1, 58 (1974)

  9. 9.

    Godal, T., Klepp, O., Onsrud, M.: Mitogenic effect of Corynebacterium parvum on T-lymphocytes of human peripheral blood. Cancer Immunol. Immunother. 3, 69 (1977)

  10. 10.

    Goldstein, A. E., Cohen, G. H., Rossio, J. L., Thurman, G. B., Brown, C. N., Ulrich, J. T.: Use of thymosin in the treatment of primary immunodeficiency diseases and cancer. Med. Clin. North Am. 60, 591 (1976)

  11. 11.

    Gutterman, J. U., Mavligit, G. M., Blumenschein, G., Burgess, M. A., McBride, C. M., Hersh, E. M.: Immunotherapy of human solid tumors with bacillus Calmette Guérin: Prolongation of disease free interval and survival in malignant melanoma, breast and colorectal cancer. Ann. NY Acad. Sci. 277, 135 (1976)

  12. 12.

    Hadden, J. W., Coffey, R. G., Hadden, E. M., Lopez-Coorales, E., Sunshine, G. H.: Synthetic immunoregulating molecules. A potential bridge between cytostatic chemotherapy and immunotherapy of cancer. Cancer Immunol. Immunother. 3, 219 (1978)

  13. 13.

    Johnson, G., Audibert, F., Chedid, L.: Effects of levamisole and imidazole on lymphocyte proliferation and cyclic nucleotide levels. Cell. Immunol. 20, 98 (1975)

  14. 14.

    Luckenbach, G. A., Campeao, D. C., Modolell, M. L., Munder, P. G., Bicker, U., Hebold, G.: Immunomodulation by a new synthetic compound 2-[2-cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, BM 12 531. J. Appl. Immunol. (in press, 1979)

  15. 15.

    Mastrangelo, M. J., Berd, D., Bellet, R. E.: Critical review of previously reported clinical trials with nonspecific immunostimulants. Ann. NY Acad. Sci. 277, 94 (1976)

  16. 16.

    Mathé, G.: Cancer active immunotherapy: immunoprophylaxis and immunorestoration. An introduction. Heidelberg, New York: Springer 1976

  17. 17.

    Mathé, G.: Interspersion of chemotherapy and active systemic immunotherapy. Experimental and rational basis. Cancer Immunol. Immunother. 3, 1 (1977)

  18. 18.

    Mathé, G., Halle-Pannenko, O., Florentin, I., Bruley-Rosset, M., Kamel, M., Hui, I. J., Bourut, C.: The second generation of EORTC-ICIG experimental screening for systemic immunity adjuvants. Its significance for cancer immunotherapy: a comparison of BCG and its hydrosoluble extract. Eur. J. Cancer 11, 801 (1975)

  19. 19.

    Micksche, M., Cerni, Ch., Kokron, O., Titscher, R., Wrba, H.: Stimulation of immune response in lung cancer patients by vitamin A therapy. Oncology 34, 234 (1977)

  20. 20.

    Micksche, M., Kokoschka, E. M., Sagaster, P., Bicker, U.: Phase I and II study of BM 06 002, a new immunostimulating compound for cancer patients. Curr. Chemother. 1010 (1978a)

  21. 21.

    Micksche, M., Kokoschka, E. M., Sagaster, P., Bicker, U.: Phase I study for a new immunostimulating drug, BM 06 002, in man. In: Immune modulation and control of neoplasia by adjuvant therapy. Prog. Cancer Res. Ther. 7, 403 (1978b)

  22. 22.

    Micksche, M., Kokoschka, E. M., Sagaster, P., Bicker, U.: BM 12 531-induced immunorestoration in cancer patients. (in press, 1978c)

  23. 23.

    Milas, L., Scott, M. T.: Antitumor activity of Corynebacterium parvum. Adv. Cancer Res. 26, 257 (1978)

  24. 24.

    Mitchell, M. S., Mokyr, M. B., Kahane, I.: Stimulation of lymphoid cells by components of BCG. J. Natl. Cancer Inst. 55, 1337 (1975)

  25. 25.

    Oettgen, H. F., Pinsky, C. M., Delmonte, L.: Treatment of cancer with immunomodulators Corynebacterium parvum and levamisole. Med. Clin. North Am. 60, 622 (1976)

  26. 26.

    Schulz, J. I., Florentin, I. I., Bourut, C., Bicker, U., Mathé, G.: Delayed type hypersensitivity response and humoral antibody formation in mice treated with a new immunostimulant, 2-[2-cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, BM 12 531. IRCS Med. Sci. 6, 215 (1978a)

  27. 27.

    Sharma, B., Kohashi, O., Mickey, M. R., Terasaki, P. I.: Effect of water-soluble adjuvants on in vitro lymphocyte immunization. Cancer Res. 35, 666 (1975)

  28. 28.

    Simmler, M. C., Bruley-Rosset, M.: Immunodeficiency in cancer patients and immunorestoration. Cancer Immunol. Immunother. 1, 119 (1976)

  29. 29.

    Yamamura, Y., Azuma, I., Taniyama, T., Sugimura, K., Hiraoi, F., Tokuzen, R., Okabe, M, Nakahara, W., Yasumoto, K., Ohta, M.: Immunotherapy of cancer with cell wall skeleton of mycobacterium bovis Bacillus Calmette Guérin: Experimental and clinical results. Ann. NY Acad. Sci 277, 209 (1976)

Download references

Author information

Correspondence to M. Colot.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Colot, M., Micksche, M. & Bicker, U. Enhanced PHA stimulation of cancer patients' lymphocytes by addition of BM 12531 (azimexon) in vitro. Cancer Immunol Immunother 6, 175–178 (1979). https://doi.org/10.1007/BF00205543

Download citation

Keywords

  • Cancer Patient
  • Propane
  • Cancer Research
  • Molecular Level
  • Advanced Cancer